Most Read Articles
Stephen Padilla, Yesterday
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
6 days ago
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
6 days ago
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

Trifarotene cream effective for face, trunk acne

28 May 2019
Patients with newly diagnosed acne were found to be at an increased risk of developing clinical depression compared to the general population.

Trifarotene is safe, well-tolerated and effective in treating both facial and truncal acne, according to two phase III trials.

Researchers conducted two double-blinded, randomized, vehicle-controlled trials: PERFECT 1 (n=1,208; mean age, 19.4±6.41 years; 52.1 percent female) and PERFECT 2 (n=1,212; mean age, 19.7±6.3 years; 57.3 percent female). In both studies, the primary endpoints were success rate on the face, as measured by the Investigator’s Global Assessment (IGA), and the absolute change from baseline in inflammatory and noninflammatory counts.

In PERFECT 1, the IGA success rate in the face in patients who received the trifarotene cream (n=612) was 29.4 percent. This was significantly higher than the corresponding rate in those randomly assigned to the vehicle cream (19.5 percent; p<0.001). A similar trend was observed for PERFECT 2 (42.2 percent vs 25.7 percent; p<0.001).

Trifarotene continued to trump the vehicle control in terms of primary endpoints. For instance, in PERFECT 1, there was a significantly greater absolute drop in inflammatory lesions in those who received the cream of interest (–19.0 vs –15.4; p<0.001). This remained true in PERFECT 2 (–24.2 vs –18.7; p<0.001).

Noninflammatory lesions likewise significantly decreased from baseline in both PERFECT 1 (–25.0 vs –17.9; p<0.001) and PERFECT 2 (–30.1 vs –21.6; p<0.001).

The significant benefits of trifarotene also extended to the trunk. The Physician’s Global Assessment success rates (PERFECT 1: 35.7 percent vs 25.0 percent; p<0.001; PERFECT 2: 42.6 percent vs 29.9 percent; p<0.001) and reductions in inflammatory (PERFECT 1: –21.4 vs –18.8; p<0.001; PERFECT 2: –25.5 vs –19.8) and noninflammatory (PERFECT 1: –21.9 vs –17.9; p<0.001; PERFECT 2: –25.9 vs –20.8; p<0.001) lesions were all significantly greater in those who received the trifarotene cream.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, Yesterday
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
6 days ago
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
6 days ago
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.